TMTakeshi Murata

Takeshi Murata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Murata has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Yoshida

    Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan

    8 shared publications
  • Chikashi Watase

    Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    7 shared publications
  • Eriko Iwamoto

    Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    7 shared publications
  • Shin Takayama

    Department of Breast Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan

    7 shared publications
  • Akihiko Suto

    Department of Breast Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo, Japan

    6 shared publications
  • Ayumi Ogawa

    Department of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    6 shared publications

Latest Publications

  • Open Access

    De-escalation of breast surgery for early stage breast cancer

    by Takeshi Murata, Tomomi Fujisawa, Fumikata Hara, Toshiyuki Ishiba, Yukinori Ozaki, Takehiko Sakai, Yasuaki Sagara, Hideo Shigematsu, Akihiko Shimomura, Kazuki Sudo, et al.

    Breast cancer treatment is rapidly evolving toward precision-based de-escalation strategies for oncological safety and minimizing treatment-related morbidity. In early stage disease, minimally invasive approaches, such as non-surgical ablation techniques, including cryoablation and radiofrequency ablation, potentially constitute alternatives to conventional surgery for carefully selected low-risk tumors. Active surveillance trials challenge the necessity of immediate surgery for low-risk ductal carcinoma in situ, reflecting a paradigm shift toward risk-adapted management. In the neoadjuvant setting, achieving radiologic and pathologic complete responses, particularly in HER2-positive and triple-negative subtypes, is being investigated to determine the feasibility of omitting breast surgery under strict imaging and biopsy-guided protocols. Circulating tumor DNA-based minimal residual disease assays offer a promising tool for refining risk stratification and potentially guiding the extent of surgery and adjuvant therapy. These strategies represent a transformative movement toward biologically tailored, response-adapted, less invasive treatments for early breast cancer to optimize quality of life without compromising long-term outcomes.


  • Open Access

    Prognostic impact of progesterone receptor status in patients with breast cancer and isolated locoregional recurrence

    by Takeshi Murata, Hiraku Kumamaru, Masayuki Yoshida, Naoko Kinukawa, Shin Takayama, Akihiko Suto, Hiromitsu Jinno, Takanori Ishida, Naoki Niikura, Shigehira Saji

    Background: The impact of progesterone receptor (PR) status on the prognosis of breast cancer after isolated locoregional recurrence (ILRR) remains unclear. This study assessed the prognostic impact of the PR status of ILRR tumors in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Methods: The study utilized data from the Japanese National Clinical Database (2004–2015), including 1,625 patients with ER+/HER2- ILRR. All participants were patients aged between 20 and 75 years at diagnosis who underwent curative surgery for ER+/HER2- primary breast cancer. Patients were classified into three groups based on the PR status of primary (p) and recurrent (r) tumors. We compared the overall survival (OS) and breast cancer-specific survival (BCSS) among the three groups using the Kaplan–Meier method with the log-rank test. ER and PR were considered positive if immunohistochemistry staining was positive in > 1% of tumor cells. For the ER expression levels in ILRR tumors, 1–10% were considered as ER-low positive. Results: Patients with PR- ILRR (pPR-/rPR- and pPR+/rPR-) had significantly worse OS and BCSS than those with PR+ ILRR (pPR+/rPR+). Factors associated with worse outcomes included lymph node metastasis, a shorter disease-free interval, ER-low positivity, and no surgery for ILRR tumor. Conclusions: This study highlights PR-negativity in ER+/HER2- ILRR tumors as a poor prognostic factor after ILRR, independent of the PR status of the primary breast cancer, emphasizing the need for tailored treatment strategies.

  • Open Access

    Safety and Effectiveness of an Integrative Treatment of Acupuncture-Based Intervention in Survivors of Breast Cancer With Postmastectomy Pain Syndrome: Protocol for a Single-Center, Single-Arm Exploratory Trial

    by Naruaki Kawasaki, Hiroto Ishiki, Naho Matsubara, Takako Ikegami, Ayaka Ishikawa, Sayaka Arakawa, Asuka Takahashi, Tomoko Uchida, Yukie Nameki, Yoko Horiguchi, et al.

    Background: Postmastectomy pain syndrome (PMPS) is a prevalent chronic pain condition that occurs after breast cancer surgery, often impairing quality of life in survivors of breast cancer. Despite its prevalence, no standardized treatment has been established. Acupuncture has been reported to be an efficacious intervention for the management of chronic pain and may be an effective treatment for PMPS. Objective: This study aims to explore the effectiveness and safety of integrative treatment of acupuncture-based intervention for PMPS. Methods: This is a single-center, single-arm, prospective interventional study. Eligible participants are patients with breast cancer who experience chronic postoperative pain in the chest, neck, or shoulder with a numerical rating scale (NRS) score ≥4, are at least 6 months postcurative treatment, have no evidence of disease recurrence, and are not receiving anticancer treatment at enrollment. Participants will receive the intervention once weekly for 12 sessions, followed by a 4-week observation period. The primary end point is the change in the average pain NRS score from baseline to week 16. Results: The study commenced in October 2023 and is scheduled to continue through March 31, 2027. The first participant was enrolled on October 24, 2023. As of the manuscript submission, 24 patients have been enrolled. Conclusions: This study will explore the potential role of an integrative treatment of acupuncture-based intervention in the management of PMPS. The results will contribute to the evidence base for acupuncture in PMPS and inform the design of future clinical studies.

  • Open Access

    Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis

    by Takeshi Murata, Masayuki Yoshida, Chikashi Watase, Hinako Maeda, Ayako Nakashoji, Ayumi Ogawa, Natsuko Ohgi, Mengge Chen, Sayako Tsubota, Akiko Maeshima, et al.

    The monarchE trial enrolled patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). Although both macrometastasis and micrometastasis were eligible, the number of patients with only micrometastasis was not reported, leaving their prognosis uncertain. This study compared outcomes of patients with 1-3 positive axillary lymph nodes (pALNs), including those with only micrometastases and those with macrometastases, according to monarchE high-risk criteria. We retrospectively reviewed 844 patients with HR-positive/HER2-negative/node-positive EBC from a prospectively maintained institutional database and classified them into four groups: Group 1, 1-3 pALNs (including macrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 2, 1-3 pALNs (only micrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 3, 1-3 pALNs (including macrometastasis) with grade < 3 tumors and tumors < 5 cm; and Group 4, 1-3 pALNs (only micrometastasis) with grade < 3 tumors and tumors < 5 cm. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) were analyzed using the Kaplan-Meier method and log-rank test. Univariable Cox models assessed associations between clinical factors and outcomes. Group 2 showed outcomes comparable to Group 1 (5-year IDFS: 80.7% vs. 83.7%; DRFS: 89.5% vs. 87.9%). In univariate analysis, only tumor size-rather than Group 2 or histological grade-was prognostic for IDFS and DRFS. Sensitivity analyses restricted to patients undergoing axillary lymph node dissection yielded consistent results. Among HR-positive/HER2-negative EBC, high-risk patients with only micrometastasis demonstrated prognoses similar to those with macrometastasis.

  • Open Access

    Evaluation of progesterone receptors with different cutoff values according to menopausal status in hormone-positive early breast cancer

    by Ayumi Ogawa, Takeshi Murata, Masayuki Yoshida, Natsuko Ohgi, Hiromi Hashiguchi, Ayako Nakashoji, Hinako Maeda, Chikashi Watase, Eriko Iwamoto, Shin Takayama

    The impact of progesterone receptor (PR) expression level on breast cancer prognosis in relation to menopausal status is unclear. This study evaluated the impact of the association between PR expression level and menopausal status on prognosis in patients with estrogen receptor (ER)-positive (> 10%)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We retrospectively identified 2,796 patients with ER-positive/HER2-negative early breast cancer and classified them into three groups based on PR expression levels: PR-high (> 10%), PR-low (1–10%), and PR-zero (< 1%). We compared the cumulative incidence of any recurrence (AR) and distant recurrence (DR) among the three groups by menopausal status. Over a median follow-up of 84.5 months, there were 324 AR and 264 DR events. In premenopausal patients, the PR-zero group (1,155 patients) had a significantly worse prognosis than did the PR-low (44 patients) and PR-high (60 patients) groups. Meanwhile, postmenopausal patients in the PR-zero (219 patients) and PR-low (167 patients) groups had similar prognosis, both significantly worse than the PR-high group (1,151 patients). Varying cutoff values of PR expression according to menopausal status could help determine more personalized treatment strategies.

  • Open Access

    Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

    by Shohei Shikata, Takeshi Murata, Masayuki Yoshida, Hiromi Hashiguchi, Yukiko Yoshii, Ayumi Ogawa, Chikashi Watase, Sho Shiino, Hirokazu Sugino, Kenjiro Jimbo, et al.

    Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics. Cohort 1 included patients with either ≥ 4 positive axillary lymph nodes or 1–3 positive nodes with histological grade 3 or tumor size ≥ 5 cm. Cohort 2 consisted of patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 ≥ 20%. Cohort 3 comprised patients with 1–3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 < 20%. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) between HER2-low (IHC1+ or IHC2+/FISH−) and HER2-zero (IHC0) groups in each cohort. In cohort 1, HER2-low patients exhibited significantly better 5-year IDFS (84.2% vs. 73.6%, p = 0.0213) and DRFS (88.2% vs. 79.8%, p = 0.0154). However, no significant differences were observed in cohorts 2 and 3. Our findings suggest HER2-low positivity as a prognostic factor in HR-positive, HER2-negative, and node-positive EBC.


  • Open Access

    Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer

    by Takeshi Murata, Masayuki Yoshida, Sho Shiino, Chikashi Watase, Ayumi Ogawa, Shohei Shikata, Hiromi Hashiguchi, Yukiko Yoshii, Hirokazu Sugino, Kenjiro Jimbo, et al.

    Background: Histological grade (HG) has been used in the MonrachE trial to select patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive high-risk early breast cancer (EBC). Although nuclear grade (NG) is widely used in Japan, it is still unclear whether replacing HG with NG can appropriately select high-risk patients. Methods: We retrospectively reviewed 647 patients with HR-positive, HER2-negative, node-positive EBC and classified them into the following four groups: group 1: ≥ 4 positive axillary lymph nodes (pALNs) or 1–3 pALNs and either grade 3 of both grading systems or tumors ≥ 5 cm; group 2: 1–3 pALNs, grade < 3, tumor < 5 cm, and Ki-67 ≥ 20%; group 3: 1–3 pALNs, grade < 3, tumor < 5 cm, and Ki-67 < 20%; and group 4: group 2 or 3 by HG classification but group 1 by NG classification. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) among the four groups using the Kaplan–Meier method with the log-rank test. Results: Group 1 had a significantly worse 5-year IDFS and DRFS than groups 2 and 3 (IDFS 80.8% vs. 89.5%, P = 0.0319, 80.8% vs. 95.5%, P = 0.002; DRFS 85.2% vs. 95.3%, P = 0.0025, 85.2% vs. 98.4%, P < 0.001, respectively). Group 4 also had a significantly worse 5-year IDFS (78.0%) and DRFS (83.6%) than groups 2 and 3. Conclusions: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.


  • Open Access

    A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer

    by Takeshi Murata, Masayuki Yoshida, Sho Shiino, Ayumi Ogawa, Chikashi Watase, Kaishi Satomi, Kenjiro Jimbo, Akiko Maeshima, Eriko Iwamoto, Shin Takayama, et al.

    Purpose: The impact of progesterone receptor (PR) status on the prognosis of breast cancer after isolated locoregional recurrence (ILRR) remains unclear. This study evaluated the impact of clinicopathologic factors, including PR status of ILRR, on distant metastasis (DM) after ILRR. Methods: We retrospectively identified 306 patients with ILRR diagnosed at the National Cancer Center Hospital between 1993 and 2021 from the database. Cox proportional hazards analysis was performed to examine factors associated with DM after ILRR. We developed a risk prediction model based on the number of detected risk factors and estimated survival curves using the Kaplan–Meier method. Results: During a median follow-up time of 4.7 years after ILRR diagnosis, 86 patients developed DM, and 50 died. Multivariate analysis revealed that seven risk factors were associated with poor distant metastasis-free survival (DMFS): estrogen receptor-positive/PR-negative/human epidermal growth factor receptor 2-negative ILRR, short disease-free interval, recurrence site other than ipsilateral breast, no-resection of ILRR tumor, chemotherapy for the primary tumor, nodal stage in the primary tumor, and no endocrine therapy for ILRR. The predictive model classified patients into 4 groups based on the number of risk factors: low-, intermediate-, high-, and the highest-risk groups with 0 to 1, 2, 3 to 4, and 5 to 7 factors, respectively. This revealed significant variation in DMFS among the groups. A higher number of the risk factors was associated with poorer DMFS. Conclusion: Our prediction model, which considered the ILRR receptor status, may contribute to the development of a treatment strategy for ILRR.


  • Open Access

    Development and validation of a pre- and intra-operative scoring system that distinguishes between non-advanced and advanced axillary lymph node metastasis in breast cancer with positive sentinel lymph nodes: a retrospective study

    by Takeshi Murata, Chikashi Watase, Sho Shiino, Arisa Kurita, Ayumi Ogawa, Kenjiro Jimbo, Eriko Iwamoto, Masayuki Yoshida, Shin Takayama, Akihiko Suto

    Background: There are currently no scoring-type predictive models using only easily available pre- and intraoperative data developed for assessment of the risk of advanced axillary lymph node metastasis (ALNM) in patients with breast cancer with metastatic sentinel lymph nodes (SLNs). We aimed to develop and validate a scoring system using only pre- and intraoperative data to distinguish between non-advanced (≤ 3 lymph nodes) and advanced (> 3 lymph nodes) ALNM in patients with breast cancer with metastatic SLNs. Methods: We retrospectively identified 804 patients with breast cancer (cT1-3cN0) who had metastatic SLNs and had undergone axillary lymph node dissection (ALND). We evaluated the risk factors for advanced ALNM using logistic regression analysis and developed and validated a scoring system for the prediction of ALNM using training (n = 501) and validation (n = 303) cohorts, respectively. The predictive performance was assessed using the receiver operating characteristic (ROC) curve, area under the curve (AUC), and calibration plots. Results: Ultrasound findings of multiple suspicious lymph nodes, SLN macrometastasis, the ratio of metastatic SLNs to the total number of SLNs removed, and the number of metastatic SLNs were significant risk factors for advanced ALNM. Clinical tumor size and invasive lobular carcinoma were of borderline significance. The scoring system based on these six variables yielded high AUCs (0.90 [training] and 0.89 [validation]). The calibration plots of frequency compared to the predicted probability showed slopes of 1.00 (training) and 0.85 (validation), with goodness-of-fit for the model. When the cutoff score was set at 4, the negative predictive values (NPVs) of excluding patients with advanced ALNM were 96.8% (training) and 96.9% (validation). The AUC for predicting advanced ALNM using our scoring system was significantly higher than that predicted by a single independent predictor, such as the number of positive SLNs or the proportion of positive SLNs. Similarly, our scoring system also showed good discrimination and calibration ability when the analysis was restricted to patients with one or two SLN metastases. Conclusion: Our easy-to-use scoring system can exclude advanced ALNM with high NPVs. It may contribute to reducing the risk of undertreatment with adjuvant therapies in patients with metastatic SLNs, even if ALND is omitted.